Investing.com-- Daiichi Sankyo (TYO:4568) reported stronger earnings for the first half of its fiscal year, supported by robust demand for its cancer treatments and a weaker yen, as the Japanese drugmaker maintained its full-year forecasts.
Core operating profit rose 46.9% from a year earlier to 221.3 billion yen ($1.41 billion) in the six months ended Sept. 30, while revenue increased 19.7% to 1.17 trillion yen, the company said on Friday.
Shares of the company rose 3.7% to 2,714.5 yen by 04:56 GMT.
Operating profit climbed 34.4% to 193.8 billion yen, while profit attributable to owners rose 15.8% to 151.5 billion yen.
Growth was led by its oncology business, where revenue surged 54.8% to 422.6 billion yen, driven by sales of its flagship cancer drug Enhertu and newer treatment Datroway in the United States and Europe. Foreign-exchange movements added 73.9 billion yen to revenue.
However, selling, general and administrative expenses increased 26.3% as profit-sharing payments to partner AstraZeneca rose, while research and development spending grew 10.7% to 240.1 billion yen.
Daiichi Sankyo maintained its fiscal 2026 forecast for revenue of 2.34 trillion yen and core operating profit of 360 billion yen. It expects annual profit attributable to owners of 251 billion yen and plans to raise its annual dividend to 100 yen per share from 78 yen.
Original Article
Daiichi Sankyo's first-half profit rises on cancer drug growth; shares up
Murata raises full-year outlook as AI demand drives 41% profit growth
Apple supplier Luxshare falls as Q3 profit growth slows; 9M profit misses forecast
